INS and type 1 diabetes mellitus: Taking into consideration the results obtained in this study, the two EVOO phenolic compounds used do not modify the metabolic profile in the experimental model of type 1 diabetes mellitus, therefore their use could be suggested as an adjunct to the main treatment (insulin, diet, physical exercise) in order to prevent the appearance and development of diabetic neuropathy.